Suggested Learning

SGLT2 inhibitors: A new hope for heart failure?

Sodium-glucose co-transporter-2 (SGLT2) inhibitors could revolutionise heart failure treatment, suggests new research from the University of East Anglia (UEA).

Early studies had shown that dapagliflozin, canagliflozin and empagliflozin, which are traditionally used to treat diabetes, could help around half of heart failure patients – those with the reduction ejection fraction form of the disease.

But findings published in the European Journal of Preventive Cardiology suggest they could also benefit patients with preserved ejection fraction heart failure. 

The researchers analysed previously published studies, including data from almost 10,000 patients. Lead researcher Professor Vass Vassiliou, from UEA’s Norwich Medical School, said: "We found that patients taking SGLT2 inhibitors were 22 per cent less likely to die from heart-related causes or be hospitalised for heart failure exacerbation than those taking placebo.

"This is very important because this is the first medication that can provide a benefit to this previously untreatable group of patients."

This website is for healthcare professionals, people who work in pharmacy and pharmacy students. By clicking into any content, you confirm this describes you and that you agree to Pharmacy Network News's Terms of Use and Privacy Policy.

We use essential, performance, functional and advertising cookies to give you a better web experience. Find out how to manage these cookies here. We also use Interest Based Advertising Cookies to display relevant advertisements on this and other websites based on your viewing behaviour. By clicking "Accept" you agree to the use of these Cookies and our Cookie Policy.